A Phase 2 interventional study of Delgocitinib cream and Delgocitinib cream vehicle in Chronic Hand Eczema, sponsored by LEO Pharma. Completed at 28 sites in 3 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2025-03-12.
Sponsored by LEO Pharma · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 13 studies in Eczema by LEO Pharma — 1 open to participants now, 1 under way, none of them phase 3. Eczema · LEO Pharma.
Among the 13 studies in Eczema by LEO Pharma, this one is the 6th largest by enrollment of the 12 interventional ones that give a count, is one of 2 that started in 2018, is one of 3 in phase 2, and was the 5th registered.
506 studies on the registry are indexed under Eczema; 90 are open to participants now.
Browse Eczema studies →1 of the 13 studies in Eczema by LEO Pharma is open now, in 1 country. Recruiting first, the newest first:
LEO Pharma · Sites in Germany
Ages 18+
By country, each count listing its studies:
Of the 66 Eczema studies recruiting now, 31 (47%) set no upper age limit and 27 (41%) stop at 75 or younger; 35 take children under 18; 22 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
13 studies; the count open now beside each. This study's row is marked.
First in 2006; this study’s year is marked. 2 started in 2018.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 258 is above the median of 91 across 403 interventional studies indexed under Eczema.
Median enrollment 178 across the 12 interventional studies, 1,000 across the 1 observational. Of the 12 that completed or were terminated, 6 (50%) have results posted.
This tab as a report to print or save as PDF → With an account.
LEO Pharma is the lead sponsor of 225 studies on the registry; 5 are open to participants now.
Of its 32 completed or terminated interventional studies of FDA-regulated products, 24 (75%) have results posted.
None of the studies under way reaches primary completion within a year.
Among the 13 studies in Eczema by LEO Pharma, from their registry updates:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
The purpose of this research trial was to test different strengths of a new trial medication, delgocitinib cream 1, 3, 8, and 20 mg/g, and to investigate how treatment with delgocitinib cream affects chronic hand eczema. This was judged by a range of assessments that rate the severity and extent of chronic hand eczema and its symptoms, as well as general health status and quality of life.
Key Inclusion Criteria:
Key Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
Vaccines made with a weakened form of the germ, such as measles–mumps–rubella (MMR), chickenpox and yellow fever. They can be risky when the immune system is weakened. Flu injections are not live; the nasal flu spray is.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
Corticosteroids (steroids)
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Immunosuppression
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Live vaccines
Vaccines made with a weakened form of the germ, such as measles–mumps–rubella (MMR), chickenpox and yellow fever. They can be risky when the immune system is weakened. Flu injections are not live; the nasal flu spray is.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis B tests
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis C tests
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Delgocitinib cream applied twice daily for 16 weeks.
Drug: Delgocitinib cream
Delgocitinib cream applied twice daily for 16 weeks.
Drug: Delgocitinib cream
Delgocitinib cream applied twice daily for 16 weeks.
Drug: Delgocitinib cream
Delgocitinib cream applied twice daily for 16 weeks.
Drug: Delgocitinib cream
Delgocitinib cream vehicle applied twice daily for 16 weeks.
Drug: Delgocitinib cream vehicle
Cream for topical application.
Also known as: LEO 124249 cream
The cream vehicle is similar to the delgocitinib cream except that it does not contain any active ingredient.
Also known as: LEO 124249 cream vehicle
Investigator's Global Assessment for Chronic Hand Eczema (IGA-CHE) Score of 0 (Clear) or 1 (Almost Clear) With at Least a 2-step Improvement (IGA-CHE Treatment Success) From Baseline to Week 16.
IGA-CHE is an instrument used in clinical trials to rate the severity of subject's global disease stage and is based on a 5-point scale ranging from 0 (clear) to 4 (severe). The multiple comparison procedure - modelling (MCP-Mod) approach was used to guide dose selection. Cochran-Mantel-Haenszel analysis was used to determine the difference in response rates between the active delgocitinib cream doses and delgocitinib cream vehicle.
Time frame: Week 0 to Week 16.
Change in Hand Eczema Severity Index (HECSI) From Baseline to Week 16.
HECSI is an instrument used in clinical trials to rate the severity of 6 clinical signs of hand eczema and the extent of the lesions on each of 5 hand areas by use of standard scales. The total HECSI score is based on a 4-point severity scale ranging from 0 (none/absent) to 3 (severe) and a 5-point scale rating the affected area(s) ranging from 0 (0% affected area) to 4 (76% to 100% affected area). The lowest HECSI score is 0 and the highest possible is 360. A higher HECSI score is indicating more severe hand eczema. The multiple comparison procedure - modelling (MCP-Mod) approach was used to guide dose selection. A mixed model for repeated measurements (MMRM) analysis was used to determine the difference in the continuous endpoint between the active delgocitinib cream doses and delgocitinib cream vehicle.
Time frame: Week 0 to Week 16.
Time to IGA-CHE Treatment Success.
Time to IGA-CHE treatment success response is defined as the time from baseline to first assessment of an IGA-CHE score of 0 (clear) or 1 (almost clear) with at least a 2-step improvement.
Time frame: Week 0 to Week 16.
258 participants from 26 sites in 3 countries (U.S., Denmark, Germany) were randomised in this trial. The first participant was screened on 28-Nov-2018 and the last participant completed the trial on 20-Apr-2020.
| Milestone | Delgocitinib Cream 1 mg/g | Delgocitinib Cream 3 mg/g | Delgocitinib Cream 8 mg/g | Delgocitinib Cream 20 mg/g | Delgocitinib Cream Vehicle |
|---|---|---|---|---|---|
| Started | 52 | 51 | 52 | 53 | 50 |
| Completed | 40 | 38 | 44 | 46 | 36 |
| Not completed | 12 | 13 | 8 | 7 | 14 |
| Withdrew: Lack of efficacy | 1 | 3 | 4 | 0 | 4 |
| Withdrew: Adverse event | 6 | 6 | 0 | 1 | 3 |
| Withdrew: Withdrawal by subject | 4 | 4 | 3 | 5 | 5 |
| Withdrew: Lost to follow-up | 1 | 0 | 0 | 1 | 1 |
| Withdrew: Other personal reasons | 0 | 0 | 1 | 0 | 1 |
IGA-CHE is an instrument used in clinical trials to rate the severity of subject's global disease stage and is based on a 5-point scale ranging from 0 (clear) to 4 (severe). The multiple comparison procedure - modelling (MCP-Mod) approach was used to guide dose selection. Cochran-Mantel-Haenszel analysis was used to determine the difference in response rates between the active delgocitinib cream doses and delgocitinib cream vehicle.
| Participants | Delgocitinib Cream 1 mg/g | Delgocitinib Cream 3 mg/g | Delgocitinib Cream 8 mg/g | Delgocitinib Cream 20 mg/g | Delgocitinib Cream Vehicle |
|---|---|---|---|---|---|
| Investigator's Global Assessment for Chronic Hand Eczema (IGA-CHE) Score of 0 (Clear) or 1 (Almost Clear) With at Least a 2-step Improvement (IGA-CHE Treatment Success) From Baseline to Week 16. | 11 | 4 | 19 | 20 | 4 |
HECSI is an instrument used in clinical trials to rate the severity of 6 clinical signs of hand eczema and the extent of the lesions on each of 5 hand areas by use of standard scales. The total HECSI score is based on a 4-point severity scale ranging from 0 (none/absent) to 3 (severe) and a 5-point scale rating the affected area(s) ranging from 0 (0% affected area) to 4 (76% to 100% affected area). The lowest HECSI score is 0 and the highest possible is 360. A higher HECSI score is indicating more severe hand eczema. The multiple comparison procedure - modelling (MCP-Mod) approach was used to guide dose selection. A mixed model for repeated measurements (MMRM) analysis was used to determine the difference in the continuous endpoint between the active delgocitinib cream doses and delgocitinib cream vehicle.
| score on a scale | Delgocitinib Cream 1 mg/g | Delgocitinib Cream 3 mg/g | Delgocitinib Cream 8 mg/g | Delgocitinib Cream 20 mg/g | Delgocitinib Cream Vehicle |
|---|---|---|---|---|---|
| Change in Hand Eczema Severity Index (HECSI) From Baseline to Week 16. | -39.81 ± 3.71 | -35.93 ± 3.77 | -46.69 ± 3.63 | -41.99 ± 3.59 | -26.40 ± 3.80 |
Time to IGA-CHE treatment success response is defined as the time from baseline to first assessment of an IGA-CHE score of 0 (clear) or 1 (almost clear) with at least a 2-step improvement.
| days, median | Delgocitinib Cream 1 mg/g | Delgocitinib Cream 3 mg/g | Delgocitinib Cream 8 mg/g | Delgocitinib Cream 20 mg/g | Delgocitinib Cream Vehicle |
|---|---|---|---|---|---|
| Time to IGA-CHE Treatment Success. | NA | NA | 82 | 98 | NA |
Collected over 18 weeks (from first application of IMP up until the last visit (safety follow-up visit)). Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Delgocitinib Cream 1 mg/g | 0/52 (0%) | 0/52 (0%) | 20/52 (38.5%) |
| Delgocitinib Cream 3 mg/g | 0/51 (0%) | 2/51 (3.9%) | 25/51 (49%) |
| Delgocitinib Cream 8 mg/g | 0/52 (0%) | 1/52 (1.9%) | 25/52 (48.1%) |
| Delgocitinib Cream 20 mg/g | 0/53 (0%) | 0/53 (0%) | 26/53 (49.1%) |
| Delgocitinib Cream Vehicle | 0/50 (0%) | 0/50 (0%) | 24/50 (48%) |
| Event | Delgocitinib Cream 1 mg/g | Delgocitinib Cream 3 mg/g | Delgocitinib Cream 8 mg/g | Delgocitinib Cream 20 mg/g | Delgocitinib Cream Vehicle |
|---|---|---|---|---|---|
| Dizziness posturalNervous system disorders | 0/52 | 1/51 | 0/52 | 0/53 | 0/50 |
| PemphigoidSkin and subcutaneous tissue disorders | 0/52 | 1/51 | 0/52 | 0/53 | 0/50 |
| AnxietyPsychiatric disorders | 0/52 | 0/51 | 1/52 | 0/53 | 0/50 |
| Event | Delgocitinib Cream 1 mg/g | Delgocitinib Cream 3 mg/g | Delgocitinib Cream 8 mg/g | Delgocitinib Cream 20 mg/g | Delgocitinib Cream Vehicle |
|---|---|---|---|---|---|
| NasopharyngitisInfections and infestations | 9/52 | 15/51 | 15/52 | 14/53 | 20/50 |
| EczemaSkin and subcutaneous tissue disorders | 5/52 | 4/51 | 3/52 | 6/53 | 8/50 |
| HeadacheNervous system disorders | 2/52 | 2/51 | 6/52 | 4/53 | 2/50 |
| InfluenzaInfections and infestations | 1/52 | 1/51 | 0/52 | 4/53 | 0/50 |
| Dermatitis atopicSkin and subcutaneous tissue disorders | 1/52 | 3/51 | 0/52 | 0/53 | 0/50 |
| PruritusSkin and subcutaneous tissue disorders | 3/52 | 2/51 | 1/52 | 3/53 | 1/50 |
| ToothacheGastrointestinal disorders | 3/52 | 1/51 | 0/52 | 0/53 | 0/50 |
| Back painMusculoskeletal and connective tissue disorders | 1/52 | 0/51 | 2/52 | 3/53 | 1/50 |
| Age, Continuous(years) | Delgocitinib Cream 1 mg/g | Delgocitinib Cream 3 mg/g | Delgocitinib Cream 8 mg/g | Delgocitinib Cream 20 mg/g | Delgocitinib Cream Vehicle | Total |
|---|---|---|---|---|---|---|
| Mean | 44.3 ± 13.6 | 46.1 ± 14.6 | 47.9 ± 12.9 | 43.9 ± 15.1 | 47.8 ± 16.2 | 46.0 ± 14.5 |
| Sex: Female, Male(Participants) | Delgocitinib Cream 1 mg/g | Delgocitinib Cream 3 mg/g | Delgocitinib Cream 8 mg/g | Delgocitinib Cream 20 mg/g | Delgocitinib Cream Vehicle | Total |
|---|---|---|---|---|---|---|
| Female | 37 | 28 | 32 | 34 | 27 | 158 |
| Male | 15 | 23 | 20 | 19 | 23 | 100 |
| Ethnicity (NIH/OMB)(Participants) | Delgocitinib Cream 1 mg/g | Delgocitinib Cream 3 mg/g | Delgocitinib Cream 8 mg/g | Delgocitinib Cream 20 mg/g | Delgocitinib Cream Vehicle | Total |
|---|---|---|---|---|---|---|
| Hispanic or Latino | 3 | 0 | 2 | 1 | 3 | 9 |
| Not Hispanic or Latino | 49 | 51 | 50 | 52 | 47 | 249 |
| Unknown or Not Reported | 0 | 0 | 0 | 0 | 0 | 0 |
| Race/Ethnicity, Customized(Participants) | Delgocitinib Cream 1 mg/g | Delgocitinib Cream 3 mg/g | Delgocitinib Cream 8 mg/g | Delgocitinib Cream 20 mg/g | Delgocitinib Cream Vehicle | Total |
|---|---|---|---|---|---|---|
| Race — White | 51 | 51 | 50 | 52 | 50 | 254 |
| Race — Asian | 1 | 0 | 1 | 1 | 0 | 3 |
| Race — Other | 0 | 0 | 1 | 0 | 0 | 1 |
| Region of Enrollment(participants) | Delgocitinib Cream 1 mg/g | Delgocitinib Cream 3 mg/g | Delgocitinib Cream 8 mg/g | Delgocitinib Cream 20 mg/g | Delgocitinib Cream Vehicle | Total |
|---|---|---|---|---|---|---|
| United States | 4 | 4 | 4 | 5 | 4 | 21 |
| Denmark | 12 | 7 | 12 | 11 | 16 | 58 |
| Germany | 36 | 40 | 36 | 37 | 30 | 179 |
| Baseline IGA-CHE score(Participants) | Delgocitinib Cream 1 mg/g | Delgocitinib Cream 3 mg/g | Delgocitinib Cream 8 mg/g | Delgocitinib Cream 20 mg/g | Delgocitinib Cream Vehicle | Total |
|---|---|---|---|---|---|---|
| 0 - Clear | 0 | 0 | 0 | 0 | 0 | 0 |
| 1 - Almost clear | 0 | 0 | 0 | 0 | 0 | 0 |
| 2 - Mild | 13 | 13 | 11 | 12 | 12 | 61 |
| 3 - Moderate | 29 | 29 | 29 | 31 | 27 | 145 |
| 4 - Severe | 10 | 9 | 12 | 10 | 11 | 52 |
| Baseline HECSI score(units on a scale) | Delgocitinib Cream 1 mg/g | Delgocitinib Cream 3 mg/g | Delgocitinib Cream 8 mg/g | Delgocitinib Cream 20 mg/g | Delgocitinib Cream Vehicle | Total |
|---|---|---|---|---|---|---|
| Mean | 59.0 ± 48.0 | 52.4 ± 35.9 | 49.5 ± 29.3 | 65.7 ± 58.3 | 52.7 ± 34.9 | 55.9 ± 42.8 |
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: No
Ran from Nov 2018 to primary completion in Mar 2020, 15 months.
Results were first posted in Apr 2021, 1 year 1 month after primary completion.
Of 54 industry-sponsored phase 2 interventional studies under Eczema, half reached primary completion within 13 months of starting (the median), counting those still running; a quarter within 9 and three quarters within 16. This study's 15 months is above that.
Counting every sponsor, half of 70 studies reached it within 14 months; a quarter within 10 and three quarters within 26.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Apr 2021. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Delgocitinib